Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Official Raw Plasma Prices for FY2017 Virtually Flat: MHLW Panel
March 6, 2017
- Panel OKs Orphan Designations for Olaparib, Inotuzumab Ozogamicin
March 6, 2017
- Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
March 6, 2017
- MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
March 6, 2017
- MHLW OKs Add’l Indications for Revlimid, Other Drugs
March 3, 2017
- Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
March 3, 2017
- Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
March 3, 2017
- MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
March 3, 2017
- New CEFP Working Group on Assessment and Analysis Launches Discussions
March 2, 2017
- Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
March 2, 2017
- MHLW to Tap NCCHD Database to Improve Pediatric Drug Use Environment
March 2, 2017
- Conduct Surprise Inspections on Wholesalers/Pharmacies by March-End, MHLW Asks Pref. Authorities
March 2, 2017
- MHLW OKs 53 NMEs in 2016
March 2, 2017
- 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
- MHLW Summons NHK, MSD over Misleading TV Program
February 28, 2017
- Pros and Cons for Setting Up “International Center for Regenerative Medicine”: LDP, Komeito Lawmakers
February 27, 2017
- AMED to Deploy “Site Coordinators” to Expedite Drug Discovery
February 24, 2017
- Is “No Gx Substitution” Column in Scripts Still Necessary? Asks Chuikyo Payer Rep
February 23, 2017
- Foreign Price Adjustment Doesn’t Make Much Sense for Drugs with Similar Meds in Japan: Industry
February 23, 2017
- Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…